Compare INSM & CVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | INSM | CVE |
|---|---|---|
| Founded | 1988 | 2009 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.2B | 34.6B |
| IPO Year | 2000 | N/A |
| Metric | INSM | CVE |
|---|---|---|
| Price | $165.46 | $16.41 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 21 | 2 |
| Target Price | ★ $188.05 | $24.00 |
| AVG Volume (30 Days) | 3.1M | ★ 10.6M |
| Earning Date | 10-30-2025 | 10-31-2025 |
| Dividend Yield | N/A | ★ 3.30% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 1.23 |
| Revenue | $447,022,000.00 | ★ $37,063,946,178.00 |
| Revenue This Year | $43.10 | N/A |
| Revenue Next Year | $128.25 | N/A |
| P/E Ratio | ★ N/A | $13.80 |
| Revenue Growth | ★ 30.34 | N/A |
| 52 Week Low | $60.40 | $10.23 |
| 52 Week High | $212.75 | $18.75 |
| Indicator | INSM | CVE |
|---|---|---|
| Relative Strength Index (RSI) | 28.92 | 35.90 |
| Support Level | $192.50 | $16.81 |
| Resistance Level | $205.23 | $18.06 |
| Average True Range (ATR) | 7.18 | 0.46 |
| MACD | -3.77 | -0.18 |
| Stochastic Oscillator | 6.57 | 0.66 |
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
Cenovus Energy Inc is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 786 thousand barrels of oil equivalent per day in 2022. The company had upstream projects across Western Canada; crude oil production and natural gas and NGLs production offshore China and Indonesia. The downstream operations include upgrading and refining operations in Canada and the U.S., and commercial fuel operations across Canada.